AzTrials
AzTrials

ROPbiliROPNCT05806684

Hyperbilirubinemia and Retinopathy of Prematurity in Preterm Infants: a Retrospective Study.

An observational study of ROP and Jaundice, Neonatal, run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this retrospective observational study is to [learn about the correlation between hyperbilirubinemia and retinopathy of prematurity in preterm infants. The main question it aims to answer are: To evaluate the possible effect of neonatal jaundice linked to the presumed protective antioxidant action of… Read more about this study

Who is it for?
Any age
Conditions the study is for
ROP, Jaundice, Neonatal, Premature
What is being tested?
ROP
How many people
1,586 participants
Where
1 siteItaly
Study dates
1 May 2023to 31 Dec 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Prematures infants with Gestational age < 32 weeks and/or birth weight < 1500g

Who may be able to join

  • Gestational age < 32 weeks
  • birth weight < 1500g

Who cannot join

  • lack of data regarding the development of ROP
  • lack of data on the development of jaundice.

Trial locations and contacts

1 site in 1 country.

Giacomo Cavallaro, MD, PhD contact

+390255032234

giacomo.cavallaro@policlinico.mi.it

Silvia Gulden, MD contact

+390255032234

silvia.gulden@hotmail.it

Italy1 site
  • Neonatal Intensive Care Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

    Milan, MI, 20129

    Giacomo Cavallaro, MD, PhD, 3491453687, giacomocavallaro@gmail.com

    Ilaria Amodeo, MD

Other trials in Italy

About this study

Official title: Correlation Between Hyperbilirubinemia and Retinopathy of Prematurity in Preterm Infants of Very Low Birth Weight and Less Than 32 Weeks Gestational Age: a Retrospective Study

The goal of this retrospective observational study is to [learn about the correlation between hyperbilirubinemia and retinopathy of prematurity in preterm infants.

The main question it aims to answer are:

  • To evaluate the possible effect of neonatal jaundice linked to the presumed protective antioxidant action of bilirubin on the development of ROP, compared to a control group which, although presenting ROP, did not develop jaundice.
Read the detailed description

Retinopathy of prematurity (ROP) is a disease related to prematurity with a multifactorial and only partially known etiopathogenesis.

A better understanding of its risk factors and potential protective factors may lead to the development of better preventive and therapeutic strategies in the future and, thus, ultimately, reduce the incidence of this pathology.

The starting hypothesis of our study is based on the proven physiological antioxidant effect of bilirubin, demonstrated by various in vitro and in vivo studies: it was hypothesized that bilirubin, by its antioxidant action, could exercise a protective role against oxidative stress pathologies typical of prematurity, including ROP.

However, the antioxidant action of bilirubin in humans, particularly newborns, is still controversial. Some studies have demonstrated a role protective of bilirubin against oxidative damage in preterm infants, while others have conversely observed that hyperbilirubinemia is a risk factor for ROP.

It has been hypothesized that bilirubin exerts its antioxidant effect only under conditions of increased oxidative stress, i.e., when the remaining antioxidant mechanisms are no longer sufficient to cope with the production of highly reactive molecules, for example, under conditions of hypoxia and hyperoxia.

According to some studies, there is a threshold within which bilirubin can exert a cytoprotective action, beyond which the harmful effects prevail, especially in the brain. Therefore, it is necessary to have a cohort of large numbers of subjects to define better the role of hyperbilirubinemia in developing ROP, especially in the group of subjects most at risk, such as the preterm.

Among the variables analyzed, the investigators also included the value of fetal hemoglobin expressed as a percentage of total hemoglobin, assuming that lower fetal hemoglobin levels may be associated with a higher incidence of ROP. Fetal hemoglobin represents about 80% of total hemoglobin at birth and subsequently decreases physiologically, replaced by hemoglobin A until it reaches 5% at six months of age.

Transfusions of concentrated red blood cells derived from adults are mainly composed of hemoglobin A, leading to a greater and more rapid reduction in fetal hemoglobin values in newborns. Compared to hemoglobin A, fetal hemoglobin has a greater affinity for oxygen; therefore, lower fetal hemoglobin levels could lead to greater oxygen availability in the tissues and the retina, contributing to hyperoxia, which is known is the basis of the pathogenesis of ROP. With these premises, some studies conducted on small populations have analyzed the association between fetal hemoglobin levels and the onset of ROP with discordant results.

Primary endpoints:

  • Number of subjects who developed ROP (divided by severity)
  • Number of subjects who developed jaundice
  • Duration of jaundice (days) for each subject
  • Potential confounding variables: EG, PN, oxygen administration, number of RBC transfusions, sepsis, intraventricular hemorrhage, and necrotizing enterocolitis.

Study design:

Monocentric, retrospective cohort observation.

Inclusion criteria:

  • Gestational age < 32 weeks and/or birth weight < 1500g - born or hospitalized at the Neonatology and Neonatal Intensive Care Unit of the Foundation in the period under study (between 01/01/2010 and 12/31/2020).

Exclusion criteria:

Infants who do not meet the study inclusion requirements and who meet at least one of the following criteria will be excluded: - lack of data regarding the development of ROP - lack of data on the development of jaundice.

Procedures of the study:

Data from hospitalized infants in the period between 01 /01/2010 and 31/12/2020 will be collected retrospectively from the database of computerized medical records of the UOC Neonatology and Neonatal Intensive Care of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.

The variables that will be collected are the following:

  • general data of the newborn: date of birth, gender, PN, EG, mode of delivery, twins, and any treatments for complications of twins - pregnancy history: the presence of pathologies, complications, and therapies - perinatal data: assessment of adaptation to extrauterine life, need for resuscitation and/or drugs in the delivery room - neonatal parameters and comorbidities: fetal hemoglobin values, intraventricular hemorrhage, respiratory distress syndrome, pulmonary broncho dysplasia, necrotizing enterocolitis, patency of the ductus arteriosus, sepsis, malformations, presence, degree and possible treatment of ROP, presence, duration, and treatment of jaundice - treatments: need, type and duration of ventilation, administration of oxygen, number of transfusions of packed red blood cells The data will be collected from the database of computerized medical records (Neocare) of the UOC of Neonatology and Neonatal Intensive Care Unit of the IRCCS Ca' Granda Foundation Ospedale Maggiore Policlinico.

The source documents include all records of observations or annotations of clinical activities and all reports and records necessary for the evaluation and reconstruction of the clinical history.

The object of the study:

Correlation between neonatal indirect bilirubin jaundice and ROP. Control group: infants who, despite presenting ROP, did not develop jaundice.

Number of patients:

Number of patients planned for the study: 1586.

Statistic Analysis:

Population demographic characteristics and jaundice severity will be presented for the whole population using descriptive statistics.

Continuous variables will be shown using mean (standard deviation) for symmetric variables or median (interquartile range) for skewed variables and number (%) for categorical variables.

Comparing the patients with and without jaundice, categorical variables will be compared using Fisher's exact test. In contrast, continuous variables will be compared using a t-test (symmetric variables) or Mann-Whitney U test (asymmetric variables). Regarding comparing groups with different durations of jaundice, categorical variables will be compared using Fisher's exact test. In contrast, continuous variables will be compared using one-way ANOVA (symmetric variables) or the Kruskal-Wallis test (asymmetric variables).

All tests performed are two-tailed, and p-values < 0.05 are considered significant. All analyses will be performed using R software version 4.0.1 or higher (R Foundation for Statistical Computing, Vienna, Austria).

Financing: None

GCP statement: This study will be conducted in accordance with the protocol, rules of the ICH/GCP (International Council for Harmonization/Good Clinical Practice), and applicable regulations, including the June 1964 Declaration of Helsinki, as amended by the last World Medical Association General Assembly in Seoul in 2008.

Being tested
ROP
Medical subject headings
Jaundice, Neonatal, Premature Birth, Blindness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ROPOther

    Also called Jaundice

    Correlation between neonatal indirect bilirubin jaundice and ROP.

Study groups in NCT05806684
Study groupRoleWhat they receive
Prematures with jaundice and ROPCorrelation between neonatal indirect bilirubin jaundice and ROP.
Receives: Other: ROP
Prematures with ROP without jaundice.Infants who, despite presenting ROP, did not develop jaundice.
Receives: Other: ROP

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of subjects who developed Retinopathy of Prematurity (ROP) (divided by severity)

    Retinopathy of Prematurity (ROP)

    Measured: between 01/01/2010 and 12/31/2020

  2. Number of subjects who developed jaundice

    Jaundice

    Measured: between 01/01/2010 and 12/31/2020

  3. Duration of jaundice (days) for each subject

    Days of jaundice

    Measured: between 01/01/2010 and 12/31/2020

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Apr 2023
  2. Study start1 May 2023 (estimated)
  3. Primary completion30 Nov 2023 (estimated)
  4. Study completion31 Dec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
1,586 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05806684
Sponsor's protocol ID
biliROP
Acronym
biliROP
Status last verified
Apr 2023
First submitted
27 Mar 2023
Last updated
24 Apr 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Stocker R, Glazer AN, Ames BN. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5918-22. doi: 10.1073/pnas.84.16.5918.

    PubMed 3475708
  • Hammermann C, Goldstein R, Kaplan M, Eran M, Goldschmidt D, Eidelman AI. Bilirubin in the premature: toxic waste or natural defense? Clin Chem. 1998 Dec;44(12):2551-3. No abstract available.

    PubMed 9882171
  • Hegyi T, Goldie E, Hiatt M. The protective role of bilirubin in oxygen-radical diseases of the preterm infant. J Perinatol. 1994 Jul-Aug;14(4):296-300.

    PubMed 7965225
  • Gopinathan V, Miller NJ, Milner AD, Rice-Evans CA. Bilirubin and ascorbate antioxidant activity in neonatal plasma. FEBS Lett. 1994 Aug 1;349(2):197-200. doi: 10.1016/0014-5793(94)00666-0.

    PubMed 8050565
  • Teng RJ, Wu TJ, Yau KI. Retinopathy of prematurity in very-low-birthweight neonates: epidemiology and risk factors. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1997 Sep-Oct;38(5):370-4.

    PubMed 9401181
  • Dani C, Martelli E, Bertini G, Pezzati M, Filippi L, Rossetti M, Rizzuti G, Rubaltelli FF. Plasma bilirubin level and oxidative stress in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2003 Mar;88(2):F119-23. doi: 10.1136/fn.88.2.f119.

    PubMed 12598500
  • Yigit S, Yurdakok M, Kilin K, Oran O, Erdem G, Tekinalp G. Serum malondialdehyde concentration in babies with hyperbilirubinaemia. Arch Dis Child Fetal Neonatal Ed. 1999 May;80(3):F235-7. doi: 10.1136/fn.80.3.f235.

    PubMed 10212090
  • Benaron DA, Bowen FW. Variation of initial serum bilirubin rise in newborn infants with type of illness. Lancet. 1991 Jul 13;338(8759):78-81. doi: 10.1016/0140-6736(91)90074-y.

    PubMed 1676469
  • Shekeeb Shahab M, Kumar P, Sharma N, Narang A, Prasad R. Evaluation of oxidant and antioxidant status in term neonates: a plausible protective role of bilirubin. Mol Cell Biochem. 2008 Oct;317(1-2):51-9. doi: 10.1007/s11010-008-9807-4. Epub 2008 Jun 17.

    PubMed 18560765
  • Gabbianelli M, Testa U, Morsilli O, Pelosi E, Saulle E, Petrucci E, Castelli G, Giovinazzi S, Mariani G, Fiori ME, Bonanno G, Massa A, Croce CM, Fontana L, Peschle C. Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complex. Haematologica. 2010 Aug;95(8):1253-60. doi: 10.3324/haematol.2009.018259. Epub 2010 Mar 19.

    PubMed 20305142
  • De Halleux V, Truttmann A, Gagnon C, Bard H. The effect of blood transfusion on the hemoglobin oxygen dissociation curve of very early preterm infants during the first week of life. Semin Perinatol. 2002 Dec;26(6):411-5. doi: 10.1053/sper.2002.37313.

    PubMed 12537312
  • Barkemeyer BM, Hempe JM. Effect of transfusion on hemoglobin variants in preterm infants. J Perinatol. 2000 Sep;20(6):355-8. doi: 10.1038/sj.jp.7200392.

    PubMed 11002873
  • Pheng E, Lim ZD, Tai Li Min E, Rostenberghe HV, Shatriah I. Haemoglobin Levels in Early Life among Infants with and without Retinopathy of Prematurity. Int J Environ Res Public Health. 2021 Jul 1;18(13):7054. doi: 10.3390/ijerph18137054.

    PubMed 34280989
  • Hellstrom W, Martinsson T, Morsing E, Granse L, Ley D, Hellstrom A. Low fraction of fetal haemoglobin is associated with retinopathy of prematurity in the very preterm infant. Br J Ophthalmol. 2022 Jul;106(7):970-974. doi: 10.1136/bjophthalmol-2020-318293. Epub 2021 Feb 5.

    PubMed 33547036
  • Fierson WM; American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening Examination of Premature Infants for Retinopathy of Prematurity. Pediatrics. 2018;142(6):e20183061. Pediatrics. 2019 Mar;143(3):e20183810. doi: 10.1542/peds.2018-3810. No abstract available.

    PubMed 30824604

Questions about this trial

What is this clinical trial studying?

An observational study of ROP and Jaundice, Neonatal, run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 24 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Giacomo Cavallaro, MD, PhD (+390255032234, giacomo.cavallaro@policlinico.mi.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of subjects who developed Retinopathy of Prematurity (ROP) (divided by severity) (time frame: between 01/01/2010 and 12/31/2020). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05806684, which also lists 15 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in